Contineum Therapeutics (CTNM) 7th Annual Evercore ISI HealthCONx Healthcare Conference summary

Strategic focus and clinical pipeline

• Focus on neuroscience, inflammation, and immunology, with all targets starting from a neuroscience angle.

• Two clinical-stage assets: PIPE-307 (M1 receptor inhibitor, partnered with J&J) and PIPE-791 (LPA1 receptor antagonist).

• PIPE-307 is in Phase II for relapsing-remitting MS, with full enrollment expected in the first half of next year; J&J to initiate a Phase II study in depression later this year.

• PIPE-791 targets progressive MS and idiopathic pulmonary fibrosis (IPF), with Phase II studies in both indications planned for 2025.

• Exploratory Phase 1b study for PIPE-791 in pain (osteoarthritis and lower back pain) recently announced.

Differentiation and rationale for LPA1 antagonism

• LPA1 antagonism in IPF is supported by mechanistic rationale and clinical validation from prior studies.

• PIPE-791 is differentiated by high receptor occupancy and improved pharmacokinetics compared to previous compounds, such as Amgen's, which suffered from high protein binding and low bioavailability.

• PET receptor occupancy studies are used to optimize dosing and de-risk clinical development.

• The upcoming IPF Phase II trial will enroll several hundred patients, run for 26 weeks, and is expected to start mid-2025, with a readout anticipated in 2027.

Progressive MS and pain program details

• Progressive MS remains an area of high unmet need, with current treatments offering limited benefit.

• PIPE-791 aims to address both remyelination and neuroinflammation, with endpoints including imaging and functional measures.

• The progressive MS Phase II study is expected to start by the end of 2025, following completion of PET and toxicology studies in the first half of the year.

• The pain study is a small, placebo-controlled, crossover design in 40 patients, aiming to detect a signal between baseline and treatment.